ONCY today
$0.38-$0.03 (-7.24%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bullish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $0.27
Key levels
Resistance$0.53
Resistance$0.46
Support$0.38
Support$0.33
Latest news & SEC filings
DealOncolytics Biotech inks pact to supply pelareorep for trial
DealOncolytics Biotech to test pelareorep with Coherus Oncology's LOQTORZI under new supply pact
ProductOncolytics Biotech Shares Study Findings on Pelareorep in Multiple Myeloma
All ONCY news →About Oncolytics Biotech
Oncolytics Biotech is a drug developer focused on pelareorep, an intravenously given immunotherapy derived from a proprietary reovirus isolate. Pelareorep is intended to infect cancer cells selectively and alter the tumor microenvironment so the immune system can better attack tumors. The company tests it alongside chemotherapies and immunotherapies in gastrointestinal cancers such as pancreatic, colorectal, and anal cancers, and in breast cancer. It operates in Canada and the United States and has no approved products.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
ONCOLYTICS BIOTECH INC (ONCY)
What Is the Price Target for ONCY?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ONCY a Buy or Sell Right Now?
Thesis
- •Revenue growing -91.1% YoY with UNKNOWN trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ONCY.
Start Free Trial →Is ONCY Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
3
Moat Score
NONE
1/9
Piotroski Score
-89.7
Altman Z-Score
What Is Smart Money Doing with ONCY?
Insider Signal
BUYING
14 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ONCY Growth Story
Revenue YoY
-91.1%
3yr Revenue CAGR
N/A%
EPS Growth YoY
0%
FCF Growth YoY
-0.3%
Revenue Trend
UNKNOWN
Dark Pool Trades for ONCY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ONCY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:10:30 | $0.38 | 1,000 | $$383 | BUY |
| 15:09:57 | $0.38 | 3,000 | $$1K | SELL |
| 15:09:19 | $0.38 | 2,500 | $$958 | SELL |
| 15:06:00 | $0.38 | 6,000 | $$2K | BUY |
| 15:05:36 | $0.39 | 1,000 | $$386 | BUY |
5 dark pool trades shown · $$5K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ONCOLYTICS BIOTECH INC (ONCY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ONCY — frequently asked questions
What is ONCY stock price today?
ONCOLYTICS BIOTECH INC (ONCY) is at $0.38, down 7.24% (-$0.03) at the Nov 12, 2026 close.
Why is ONCY stock moving today?
Latest ONCY news — Nov 12, 2026: Oncolytics Biotech inks pact to supply pelareorep for trial · Nov 11, 2026: Oncolytics Biotech to test pelareorep with Coherus Oncology's LOQTORZI under new supply pact
What do analysts rate ONCY?
Analyst ratings for ONCY: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did ONCY beat earnings?
ONCY last reported on Aug 12, 2026: EPS -$0.08 vs -$0.05 expected — a miss of 48.7%.
Does ONCY pay a dividend?
ONCY does not currently pay a dividend.
What are ONCY support and resistance levels?
Support: $0.38, $0.33. Resistance: $0.46, $0.53, $0.59.
What are insiders doing with ONCY?
Insider activity: BUYING, 14 buys and 0 sells in the last 90 days.
What is the latest news on ONCY?
Nov 12, 2026: Oncolytics Biotech inks pact to supply pelareorep for trial · Nov 11, 2026: Oncolytics Biotech to test pelareorep with Coherus Oncology's LOQTORZI under new supply pact · Nov 10, 2026: Oncolytics Biotech Shares Study Findings on Pelareorep in Multiple Myeloma